Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy
- PMID: 37466170
- PMCID: PMC10477133
- DOI: 10.1093/jac/dkad192
Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy
Abstract
Objectives: Cefepime is an antibiotic commonly used to treat sepsis and is cleared by renal excretion. Cefepime dosing requires adjustment in patients with decreased kidney function and in those receiving continuous kidney replacement therapy (CKRT). We aimed to characterize cefepime PK in a diverse cohort of critically ill paediatric patients on CKRT.
Methods: Patients were identified from an ongoing pharmacokinetic/pharmacodynamic (PK/PD) study of beta-lactam antibiotics, and were included if they had received at least two cefepime doses in the ICU and were on CKRT for at least 24 h. PK parameters were estimated using MwPharm++ with Bayesian estimation and a paediatric population PK model. Target attainment was assessed as time of free cefepime concentrations above minimum inhibitory concentration (fT > 1× or 4 × MIC).
Results: Seven patients were included in the study (ages 2 to 20 years). CKRT indications included liver failure (n = 1), renal failure (n = 4) and fluid overload (n = 2). Total effluent flow rates ranged from 1833 to 3115 (mean 2603) mL/1.73 m2/h, while clearance was 2.11-3.70 (mean 3.0) L/h/70 kg. Effluent flows were lower, but clearance and fT > MIC were similar to paediatric data published previously. Using Pseudomonas aeruginosa MIC breakpoints, all patients had 100% of dosing interval above MIC, but only one had 100% of dosing interval above 4× MIC.
Conclusions: Since most patients failed to attain stringent targets of 100% fT > 4× MIC, model-informed precision dosing may benefit such patients.
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures

Similar articles
-
Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment.J Intensive Care. 2024 Oct 8;12(1):38. doi: 10.1186/s40560-024-00752-0. J Intensive Care. 2024. PMID: 39380059 Free PMC article.
-
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.Pharmacotherapy. 2019 Nov;39(11):1066-1076. doi: 10.1002/phar.2332. Epub 2019 Oct 22. Pharmacotherapy. 2019. PMID: 31549737
-
Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.Clin Microbiol Infect. 2022 Sep;28(9):1287.e9-1287.e15. doi: 10.1016/j.cmi.2022.03.031. Epub 2022 Apr 4. Clin Microbiol Infect. 2022. PMID: 35390523
-
Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.J Clin Pharm Ther. 2022 Aug;47(8):1091-1102. doi: 10.1111/jcpt.13657. Epub 2022 Mar 29. J Clin Pharm Ther. 2022. PMID: 35352374 Free PMC article. Review.
-
Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.Blood Purif. 2023;52(6):503-515. doi: 10.1159/000529694. Epub 2023 May 5. Blood Purif. 2023. PMID: 37231811
Cited by
-
Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment.J Intensive Care. 2024 Oct 8;12(1):38. doi: 10.1186/s40560-024-00752-0. J Intensive Care. 2024. PMID: 39380059 Free PMC article.
References
-
- Brivet FG, Kleinknecht DJ, Loirat Pet al. . Acute renal failure in intensive care units—causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French study group on acute renal failure. Crit Care Med 1996; 24: 192–8. 10.1097/00003246-199602000-00003 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources